References
- Khachemoune A, Phillips TJ. Current treatment options in psoriasis. Hosp Pract (Off Ed) 2000;35:93–6, 101–4, 107
- Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm. 2000;57:645–62
- National Psoriasis Foundation. Psoriasis Statistics. Available from: http://www.psoriasis.org/resources/statistics/[Accessed 21 February 2003]
- Lebwohl M. Psoriasis. Lancet 2003;361:1197–204
- Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280–4
- Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850–60
- Galadari I, Rigel E, Lebwohl M. The cost of psoriasis treatment. J Eur Acad Dermatol Venereol. 2001;15:290–1
- Marchetti A, LaPensee K, An P. A pharmacoeconomic analysis or topical therapies for patients with mild-to-moderate stable plaque psoriasis: a US study. Clin Ther 1998;20:851–69
- Feldman SR, Fleischer AB Jr, Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997;37:564–9
- Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000;25:1–10
- Koo J. Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results. J Am Acad Dermatol 1999;41(3 Pt 2):S25–8
- Lebwohl M, Suad A. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487–98
- Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649–61
- Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporine for severe psoriasis. Clin Exp Dermatol 2002;27:111–4
- Griffiths CEM, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001;26:338–42
- Marcil I, Stern R. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001;358:1042–45
- D’Hoore W, Bouckaert A, Tilquin C. Practical Considerations on the Use of the Charlson Comorbidity Index with Administrative Data Bases. J Clin Epidemol 1996;49:1429–33
- Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461–94
- Manly BFJ. Randomization, Bootstrap and Monte Carlo Methods in Biology, 2nd ed. London: Chapman & Hall, 1997
- Hosmer D, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, 1989
- Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003;120:211–16
- McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety 2002;25:915–27
- Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982–6
- Lindegard B. Diseases associated with psoriasis in a general population of 159 200 middle-aged, urban, native Swedes. Dermatologica 1986;172:298–304
- Koo JYM. Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol 1999;26:723–33
- Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41(3 Pt 1):401–7
- Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995;32:982–6